Marjorie T. Buss

Marjorie T. Buss

Auto-generated profile, based on publicly available information

Marjorie T. Buss

Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAMohamad H. Abedi
Mohamad H. Abedi
MYMichael S. Yao
Michael S. Yao
DMDavid R. Mittelstein
David R. Mittelstein
ABAvinoam Bar-Zion
Avinoam Bar-Zion
MSMargaret B. Swift
Margaret B. Swift
MSMikhail G. Shapiro
Mikhail G. Shapiro
Rapid advances in synthetic biology are driving the development of genetically engineered microbes as therapeutic agents for a multitude of human diseases, including cancer. The immunosuppressive microenvironment of solid tumors, in particular, creates a favorable niche for systemically administered bacteria to engraft and release therapeutic payloads. However, such payloads can be harmful if released outside the tumor in healthy tissues where the bacteria also engraft in smaller numbers. To address this limitation, we engineer therapeutic bacteria to be controlled by focused ultrasound, a form of energy that can be applied noninvasively to specific anatomical sites such as solid tumors. This control is provided by a temperature-actuated genetic state switch that produces lasting therapeutic output in response to briefly applied focused ultrasound hyperthermia. Using a combination of rational design and high-throughput screening we optimize the switching circuits of engineered cells and connect their activity to the release of immune checkpoint inhibitors. In a clinically relevant cancer model, ultrasound-activated therapeutic microbes successfully turn on in situ and induce a marked suppression of tumor growth. This technology provides a critical tool for the spatiotemporal targeting of potent bacterial therapeutics in a variety of biological and clinical scenarios.

27 September 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
ABAvinoam Bar-Zion
Avinoam Bar-Zion
ANAtousa Nourmahnad
Atousa Nourmahnad
DMDavid R. Mittelstein
David R. Mittelstein
SSShirin Shivaei
Shirin Shivaei
SYSangjin Yoo
Sangjin Yoo
MSMikhail G. Shapiro
Mikhail G. Shapiro

2 January 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
RHRobert C. Hurt
Robert C. Hurt
MBMarjorie T. Buss
Marjorie T. Buss
MDMengtong Duan
Mengtong Duan
KWKatie Wong
Katie Wong
MYMei Yi You
Mei Yi You
MSMikhail G. Shapiro
Mikhail G. Shapiro
Ultrasound allows imaging at a much greater depth than optical methods, but existing genetically encoded acoustic reporters for in vivo cellular imaging have been limited by poor sensitivity, specificity and in vivo expression. Here we describe two acoustic reporter genes (ARGs)—one for use in bacteria and one for use in mammalian cells—identified through a phylogenetic screen of candidate gas vesicle gene clusters from diverse bacteria and archaea that provide stronger ultrasound contrast, produce non-linear signals distinguishable from background tissue and have stable long-term expression. Compared to their first-generation counterparts, these improved bacterial and mammalian ARGs produce 9-fold and 38-fold stronger non-linear contrast, respectively. Using these new ARGs, we non-invasively imaged in situ tumor colonization and gene expression in tumor-homing therapeutic bacteria, tracked the progression of tumor gene expression and growth in a mouse model of breast cancer, and performed gene-expression-guided needle biopsies of a genetically mosaic tumor, demonstrating non-invasive access to dynamic biological processes at centimeter depth.

25 July 2018 in Energy & Environmental Science
Verified
Journal Article
Open access
PDF file
XMXianwen Mao
Xianwen Mao
WTWenda Tian
Wenda Tian
YRYinying Ren
Yinying Ren
DCDexin Chen
Dexin Chen
SCSarah E. Curtis
Sarah E. Curtis
THT. Alan Hatton
T. Alan Hatton
We describe a water treatment strategy, electrochemically tunable affinity separation (ETAS), which, unlike other previously developed electrochemical processes, targets uncharged organic pollutants in water. Key to achieving ETAS resides in the development of multicomponent polymeric nanostructures that simultaneously exhibit the following characteristics: an oxidation-state dependent affinity towards neutral organics, high porosity for sufficient adsorption capacity, and high conductivity to permit electrical manipulation. A prototype ETAS adsorbent composed of nanostructured binary polymeric surfaces that can undergo an electrically-induced hydrophilic–hydrophobic transition can provide programmable control of capture and release of neutral organics in a cyclic fashion. A quantitative energetic analysis of ETAS offers insights into the tradeoff between energy cost and separation extent through manipulation of electrical swing conditions. We also introduce a generalizable materials design approach to improve the separation degree and energetic efficiency simultaneously, and identify the critical factors responsible for such enhancement via redox electrode simulations and theoretical calculations of electron transfer kinetics. The effect of operation mode and multistage configuration on ETAS performance is examined, highlighting the practicality of ETAS and providing useful guidelines for its operation at large scale. The ETAS approach is energetically efficient, environmentally friendly, broadly applicable to a wide range of organic contaminants of various molecular structures, hydrophobicity and functionality, and opens up new avenues for addressing the urgent, global challenge of water purification and wastewater management.

16 June 2022 in ACS Synthetic Biology
Verified
Journal Article
Open access
LXLealia L. Xiong
Lealia L. Xiong
MGMichael A. Garrett
Michael A. Garrett
MBMarjorie T. Buss
Marjorie T. Buss
JKJulia A. Kornfield
Julia A. Kornfield
MSMikhail G. Shapiro
Mikhail G. Shapiro
Temperature is a versatile input signal for the control of engineered cellular functions. Sharp induction of gene expression with heat has been established using bacteria- and phage-derived temperature-sensitive transcriptional repressors with tunable switching temperatures. However, few temperature-sensitive transcriptional activators have been reported that enable direct gene induction with cooling. Such activators would expand the application space for temperature control. In this technical note, we show that temperature-dependent versions of the Lambda phage repressor CI can serve as tunable cold-actuated transactivators. Natively, CI serves as both a repressor and activator of transcription. Previously, thermolabile mutants of CI, known as the TcI family, were used to repress the cognate promoters PR and PL. We hypothesized that TcI mutants can also serve as temperature-sensitive activators of transcription at CI's natural PRM promoter, creating cold-inducible operons with a tunable response to temperature. Indeed, we demonstrate temperature-responsive activation by two variants of TcI with set points at 35.5 and 38.5 °C in E. coli. In addition, we show that TcI can serve as both an activator and a repressor of different genes in the same genetic circuit, leading to opposite thermal responses. Transcriptional activation by TcI expands the toolbox for control of cellular function using globally or locally applied thermal inputs.

25 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMarjorie T. Buss
Marjorie T. Buss
LZLian Zhu
Lian Zhu
JKJamie H. Kwon
Jamie H. Kwon
JTJeffrey J. Tabor
Jeffrey J. Tabor
MSMikhail G. Shapiro
Mikhail G. Shapiro
Inflammatory bowel diseases (IBD) affect millions of people globally, result in severe symptoms, and are difficult to diagnose and monitor – often necessitating the use of invasive and costly methods such as colonoscopies or endoscopies. Engineered gut bacteria offer a promising alternative due to their ability to persist in the gastrointestinal (GI) tract and sense and respond to specific environmental signals. However, probiotics that have previously been engineered to report on inflammatory and other disease biomarkers in the Gl tract rely on fluorescent or bioluminescent reporters, whose signals cannot be resolved in situ due to the poor penetration of light in tissue, or on colorimetric reporters which rely on plating feces. To overcome this limitation, we introduce probiotic biosensors that can be imaged in situ using ultrasound – a widely available, inexpensive imaging modality providing sub-mm spatial resolution deep inside the body. These biosensors are based on the clinically approved probiotic bacterium E. coli Nissle, which we engineered to transiently colonize the GI tract, sense inflammatory biomarkers, and respond by expressing air-filled sound-scattering protein nanostructures called gas vesicles. After optimizing biomolecular signaling circuits to respond sensitively to the biomarkers thiosulfate and tetrathionate and produce strong and stable ultrasound contrast, we validated our living biosensors in vivo by noninvasively imaging antibiotic-induced inflammation in mice. By connecting cell-based diagnostic agents to ultrasound, these probiotic biosensors will potentially make it easier and cheaper to diagnose and monitor IBD or other GI conditions.